Another note from the Prospectus: Anatomical Pathology...

Another note from the Prospectus:

Anatomical Pathology Laboratory Information System (APLIS)

ImExHS has developed an Anatomical Pathology Laboratory Information System  (APLIS) which  allows healthcare organisations to manage the workflow and images in its Anatomical Pathology  Laboratory facility on ImExHS’s Hiruko™ platform.  

ImExHS’s APLIS solution has completed successfully the development stage and will be released  as beta version for a trial at Las Americas hospital during 2018, which is expected to be converted  to a commercial 5 year SaaS contract. Las Americas is one of the top private hospitals in Latin  America. ImExHS expects to have early mover advantage with its APLIS solution and plans a hard  launch of APLIS in Q4 2018.

ImExHS has an immediate opportunity to sell this practical implementation of integrated multi‐ vertical VNA into its existing customer base, as well as providing ImExHS with an additional source  of competitive advantage as it seeks to win new business in the region.

Cardiology Information System (CIS)

ImExHS  has  developed  a  Cardiology  Information  System  (CIS)  which  allows  healthcare  organisations to manage Cardiology workflow and images on its Hiruko™ platform.   ImExHS’s Hiruko™ RIS/PACS solution is currently installed at Las Americas hospital in Medellin,  Colombia, under a 5 year PaaS contract. In addition, Las Americas have already commenced a  pilot of the CIS platform. ImExHS expects to convert this CIS platform into a 5 year SaaS contract  post pilot trial, with plans for commercial launch for Q4 2018.   

The CIS market is less mature than the RIS market and ImExHS expects to leverage early mover  advantage  in  this  practical  application  of  integrated multi‐vertical  VNA,  and  has  intentions  to  cross sell this additional vertical into its existing customer base.

---------------------------------

The trial periods for Cardiology and Pathology verticals are nearing completion and about to enter commercialisation. Cardiology due this quarter and Pathology due Q1 2019.

Based on the prospectus, it would appear that Las Americas will sign up for 5 year SaaS contracts for each vertical on completion of the trials.

There may be some further contract news imminent.